Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News & insights
Publications: 11 JANUARY 2021
Will the EU-China Comprehensive Agreement facilitate investment by EU companies in China?
The European Union (EU) and the People’s Republic of China concluded the negotiations on their investment treaty, the EU/China Comprehensive Agreement on Investment (CAI), on 30 December 2020.
Read more
Publications: 21 DECEMBER 2020
In the fourth in our series of webinars, members of Allen & Overy’s Global Employment team discussed the significant issues and challenges that employers need to prioritise in relation to managing and…
Read more
Publications: 16 DECEMBER 2020
M&A market shows signs of recovery in second half
2020 has been a year of two very distinct halves but signs of recovery give grounds for optimism.
Read more
Publications: 15 DECEMBER 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Read moreDownload our sector brochure
